Versa

INJECTION DEPTH

Revanesse® Versa™ is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more.

What are the risks?

The most common reported side effects are bleeding, bruising, swelling, and pain.
Other risks that are less likely, but may occur, include Acne-like skin eruptions, skin sensitivity (rash, itching, tenderness), skin infection, damage to nerves or blood vessels, skin lumpiness, scarring, skin necrosis, hyperpigmentation, reactivation of herpes infection (blisters or skin sores).
If you have an adverse reaction or side effect that persists for one week or more after treatment with a Revanesse® dermal filler, please contact your healthcare provider.

Warning: One of the risks of being injected with any dermal filler is unintentional injection into a blood vessel. These complications, which have been reported with facial injectable fillers, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin.

WHAT MAKES REVANESSE® VERSA™ UNIQUE?

 

LESS SWELLING
In one of our clinical trials, 50% more patients treated with a comparative product experienced swelling, than patients who were treated with Revanesse® Versa™. 1

LONGEVITY
You may find that Revanesse® Versa™ will help in the improvement of your nasolabial folds (laugh lines) for up to 12 months with optimal correction. 2

DESIGNED FOR SAFETY
The Revanesse® Versa™ formula is well-studied, with over 300 patients of multiple skin types, treated in three clinical trials, with no serious adverse events reported.

IMMEDIATE RESULTS
A Revanesse® Versa™ treatment is minimally invasive and provides immediate results. Take control of the signs of aging and ask your healthcare provider if Revanesse® Versa™ is right for you.

1 Injection site swelling (47.2% [77/163] with Revanesse® Versa™, 71.1% [116/163] with Comparator)
2 Multicenter Study to Evaluate the Safety and Efficacy of Revanesse Ultra Retreatment 78.1% of subjects reported being improved, much improved, or very much improved at 52 weeks according to their pGAI scores.